Solvias’ Post

Release testing is a critical aspect of drug development, ensuring the safety, identity, quality, purity, strength, and potency of raw materials, drug substances, and drug products. With evolving drug modalities, manufacturing and testing processes become more complex. Swipe left to explore some of the factors contributing to this complexity. Solvias takes great pride in being chosen to perform release testing on the world's first CRISPR-based gene-editing therapy, CASGEVY™, developed by @Vertex Pharmaceuticals, as outlined in our recent press release. 🔗 Press release: https://lnkd.in/eqWFpz3a Contact us at info@solvias.com to discover how Solvias can assist you in navigating the logistical, regulatory, and technical requirements to bring your innovation to its destination. #genetherapy #CRISPRtherapeutics #releasetesting #casgevy

Join Dr. Chia-Hua Maggie Ho, D.Phil., in conjunction with the Taiwan Bio Industry Organization and the Maryland Department of Commerce for a virtual talk on entering the U.S. medical products market. For more information visit https://lnkd.in/enMNYmDv. Learn more about Dr. Maggie Ho, Amarex Taiwan Vice President and COO, at https://lnkd.in/ej9xdSnW. #cro #clinicalresearch #clinicaltrials #fda #fdaapproval #maryland #Taiwan #marylandbusiness #productdevelopment #regulatoryaffairs #biotech #biotechnology #pharma #pharmaceutical #medicaldevice #reseachanddevelopment #drugdevelopment

Patent expirations often lead to a shake-up within the pharmaceutical industry, compelling companies to diversify their revenue bases and prepare for the upcoming patent cliffs.   Several high-performing injectable drugs worth billions are set to lose their patent protection soon. Historically, the loss of patent protection for blockbuster drugs has introduced intense competition from both industry's leading players and emerging players   Check out our flyer for a detailed list of some of the top-performing molecules that will soon require extensive biosimilar studies, healthy volunteer ( Bioequivalence) studies, and patient trials https://bit.ly/3RS1LQN To know more, visit www.veedacr.com or write to us at info@veedacr.com Partners in creating a healthier tomorrow. #Veeda #Biotechnology #LifeSciences #VeedaBiopharma #VeedaGroup #Veedaclinicalresearch #biosimilars #InjectableDrugs

Remember when "API intermediates" was just industry jargon? In the decade since I founded INA Pharmaceuticals, that seemingly innocuous term has morphed into a silent orchestra conductor, orchestrating the delicate dance of drug development. Here's the truth: 95% of all generic drugs rely on these chemical building blocks, yet their complexities are often obscured. At INA, we specialize in API Intermediates. They're not just molecules on a page but the lifeblood of affordable healthcare. Let’s cast more light on the topic together in the next few days. Would you like to chat more about it? #api #apiintermediates #pharmaceuticals

UK drug discovery needs stronger funding effort, report shows Improvements to the ways medicines are discovered are essential for the future health of patients, a new report by Medicines Discovery Catapult (MDC) shows.  The State of the Discovery Nation (SODN) 2024: ‘Fostering a Dynamic, Sustainable Medicines Discovery Sector’ report states that the industry must work together to de-risk funding in drug discovery and attract more investors. https://lnkd.in/eH_-9XtJ #DrugDiscovery #Pharmaceutical #Biotechnology

Learn more about adaptive designs in clinical research from Hana Mekonnen at https://bit.ly/3Pa7BLP. #adaptivedesign #cro #clinicaltrial #clinicaltrials #clinicalresearch #pharma #pharmaceutical #biotech #biotechnology #medicaldevice

The European Parliament announced the adoption of a new legislation to limit cancer-causing lead and diisocyanate. The latter are widely used in different applications in industry, most notably in the manufacturing of polyurethanes. The @EU Commission will: ◻ Revise lead limits in five years time ◻ Consider updated scientific data ◻ Review rules for diisocyanates by 2029 The Council of the European Union will have to formally endorse the text before publication in the EU Official Journal and entry into force. https://bit.ly/3SImMgj #pharma #pharmaceutical #healthcare

Why is the Inflation Reduction Act creating aftershocks in the life sciences ecosystem? Because it significantly impacts pharmaceutical, biotech, and generic drug manufacturers. Jesse Mendelsohn, SVP at Model N, a revenue optimization platform provides a comprehensive overview of which types of companies will feel the aftershock and why. Watch the full clip to understand the broader implications for the life sciences industry and how different sectors will be affected. 🔗 https://lnkd.in/eRynmA7J How do you think the Inflation Reduction Act will shape the future of the life sciences industry? Share your thoughts in the comments!

There is a clear trend of strategic acquisitions across the industry, which suggests that companies are looking to bolster their portfolios quickly through external innovation. The balance between internal development and acquisition indicates a diversified strategy to mitigate risks and capitalize on new opportunities. what do you think trends in blockbuster approvals reflect shifts in the pharmaceutical industry? #Pharmaceutical #Drug #RD #Medicine

Interesting to see who has the most “blockbusters.” But also to see how varied the strategies are for internal investment vs acquisition.